Helene F. S. Negaard
- Consultant oncologist; MD, PhD
- +47 22 93 47 22
Publications 2024
Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update Consortium
Eur J Cancer, 202, 114042
DOI 10.1016/j.ejca.2024.114042, PubMed 38564927
Initial surveillance in men with marker negative clinical stage IIA non-seminomatous germ cell tumours
BJU Int, 133 (6), 717-724
DOI 10.1111/bju.16289, PubMed 38293778
Primary Retroperitoneal Lymph Node Dissection as Treatment for Low-volume Metastatic Seminoma in a Population-based Cohort: The Swedish Norwegian Testicular Cancer Group Experience
Eur Urol Open Sci, 65, 13-19
DOI 10.1016/j.euros.2024.05.006, PubMed 38966804
Publications 2023
Validation of a prediction model for post-chemotherapy fibrosis in nonseminoma patients
BJU Int, 132 (3), 329-336
DOI 10.1111/bju.16040, PubMed 37129962
Association of physical activity with overall mortality among long-term testicular cancer survivors: A longitudinal study
Int J Cancer, 153 (8), 1512-1519
DOI 10.1002/ijc.34625, PubMed 37334652
Publications 2021
Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium
J Clin Oncol, 39 (14), 1553-1562
DOI 10.1200/JCO.20.03292, PubMed 33729863
Unilateral or Bilateral Retroperitoneal Lymph Node Dissection in Nonseminoma Patients with Postchemotherapy Residual Tumour? Results from RETROP, a Population-based Mapping Study by the Swedish Norwegian Testicular Cancer Group
Eur Urol Oncol, 5 (2), 235-243
DOI 10.1016/j.euo.2021.02.002, PubMed 33750683
Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium
J Clin Oncol, 39 (14), 1563-1574
DOI 10.1200/JCO.20.03296, PubMed 33822655
Thromboembolic Events During Treatment with Cisplatin-based Chemotherapy in Metastatic Testicular Germ-cell Cancer 2000-2014: A Population-based Cohort Study
Eur Urol Open Sci, 32, 19-27
DOI 10.1016/j.euros.2021.07.007, PubMed 34667955
Testicular Cancer in the Cisplatin Era: Causes of Death and Mortality Rates in a Population-Based Cohort
J Clin Oncol, 39 (32), 3561-3573
DOI 10.1200/JCO.21.00637, PubMed 34388002
Publications 2020
Metachronous Contralateral Testicular Cancer in the Cisplatin Era: A Population-Based Cohort Study
J Clin Oncol, 39 (4), 308-318
DOI 10.1200/JCO.20.02713, PubMed 33356420
Thromboembolic events after high-intensity training during cisplatin-based chemotherapy for testicular cancer: Case reports and review of the literature
Int J Cancer, 147 (11), 3189-3198
DOI 10.1002/ijc.33151, PubMed 32525564
Publications 2019
Surgical Complications in Postchemotherapy Retroperitoneal Lymph Node Dissection for Nonseminoma Germ Cell Tumour: A Population-based Study from the Swedish Norwegian Testicular Cancer Group
Eur Urol Oncol, 3 (3), 382-389
DOI 10.1016/j.euo.2019.08.002, PubMed 31506250
Continuing increased risk of second cancer in long-term testicular cancer survivors after treatment in the cisplatin era
Int J Cancer, 147 (1), 21-32
DOI 10.1002/ijc.32704, PubMed 31597192
Publications 2013
Evidence for long-term hypercoagulopathy, but normalization of markers of extracellular matrix turnover, in patients with non-Hodgkin lymphoma
Leuk Lymphoma, 56 (8), 2479-81
DOI 10.3109/10428194.2013.803227, PubMed 23656198
Publications 2011
Associations between regulators of extracellular matrix and hemostatic factors in hematologic neoplasias
Leuk Lymphoma, 52 (6), 1157-9
DOI 10.3109/10428194.2011.563886, PubMed 21463121
Publications 2009
Alterations in regulators of the extracellular matrix in non-Hodgkin lymphomas
Leuk Lymphoma, 50 (6), 998-1004
DOI 10.1080/10428190902889270, PubMed 19373600
Publications 2008
Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors
Leukemia, 23 (1), 162-9
DOI 10.1038/leu.2008.255, PubMed 18800145
Increased acquired activated protein C resistance in unselected patients with hematological malignancies
J Thromb Haemost, 6 (9), 1482-7
DOI 10.1111/j.1538-7836.2008.03060.x, PubMed 18573186
Hypercoagulability in patients with haematological neoplasia: no apparent initiation by tissue factor
Thromb Haemost, 99 (6), 1040-8
DOI 10.1160/TH07-09-0541, PubMed 18521506
Publications 2006
Decreased lung cancer survival with hormone-replacement therapy: caused by a decreased tissue factor pathway inhibitor level?
J Clin Oncol, 24 (17), 2683-4; author reply 2684
DOI 10.1200/JCO.2006.06.4345, PubMed 16763285